COVID-19 and the Developement of Phobic Fears of Disease

NCT ID: NCT04359121

Last Updated: 2023-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-15

Study Completion Date

2023-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A lot of people suffer from phobias. Phobias concerning certain diseases are not rare. This study will examine whether the COVID-19 (Coronavirus Disease) crisis was able to rise phobias in people and if those with preexisting phobias or fears were more likely to develop a phobia concerning COVID. It will look at different subtypes - physicians, medical staff, general public (not medically affiliated) and patients with psychiatric disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Physicians

Questionnaires

Questionnaires for specific phobia

Intervention Type OTHER

Questionnaires will be used.

Medical staff

Questionnaires

Questionnaires for specific phobia

Intervention Type OTHER

Questionnaires will be used.

General public

Questionnaires

Questionnaires for specific phobia

Intervention Type OTHER

Questionnaires will be used.

Patients with psychiatric disorders

Questionnaires

Questionnaires for specific phobia

Intervention Type OTHER

Questionnaires will be used.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires for specific phobia

Questionnaires will be used.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Person gives written consent
* Persons between 18-90 years of age (men and women)
* No positive COVID infection known at time of first examination

* COVID infection known at first examination point

Exclusion Criteria

* Dementia, Delirium (not able to give consent)
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Graz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Baranyi, Prof.

Role: PRINCIPAL_INVESTIGATOR

Medical University of Graz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical University of Graz

Graz, Styria, Austria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andreas Baranyi, Prof.

Role: CONTACT

0043-316-385-86241

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andreas Baranyi, Prof. MD

Role: primary

+4331638586241

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

32-354 ex 19/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Quetiapine in Specific Phobia
NCT00872716 COMPLETED PHASE2
Treatment for Specific Phobias in Children
NCT00051220 COMPLETED PHASE1/PHASE2